Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor–positive metastatic breast cancer

By Esteva Francisco   Moulder Stacy   Gonzalez-Angulo Ana   Ensor Joe   Murray James   Green Marjorie   Koenig Kimberly   Lee Mong-Hong   Hortobagyi Gabriel   Yeung Sai-Ching  

Cancer Chemotherapy and Pharmacology, Vol. 71, Iss. 1, 2013-01 ,pp. : 63-72

Springer Publishing Company

Access to resources Recommend Favorite

Treatment Strategies for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

By Yang Wei   Chamberlin Mary D.   Miller Todd W.  

The Journal of OncoPathology, Vol. 2, Iss. 2, 2014-06 ,pp. : 33-42

Optimal Clinical Ltd

Access to resources Recommend Favorite

Histopathological assessment of anastrozole and tamoxifen as preoperative (neoadjuvant) treatment in postmenopausal Japanese women with hormone receptor-positive breast cancer in the PROACT trial

By Kurosumi Masafumi   Takatsuka Yuichi   Watanabe Toru   Imoto Shigeru   Inaji Hideo   Tsuda Hitoshi   Akiyama Futoshi   Sakamoto Goi   Ikeda Tadashi   Noguchi Shinzaburo  

Journal of Cancer Research and Clinical Oncology, Vol. 134, Iss. 6, 2008-06 ,pp. : 715-722

Springer Publishing Company

Access to resources Recommend Favorite

A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer

By Carlson Robert  

Breast Cancer Research and Treatment, Vol. 133, Iss. 3, 2012-06 ,pp. : 1049-1056

Springer Publishing Company

Access to resources Recommend Favorite

Neoadjuvant endocrine therapy for postmenopausal patients with hormone receptor-positive early breast cancer: a new concept

By Iwata Hiroji  

Breast Cancer, Vol. 18, Iss. 2, 2011-04 ,pp. : 92-97

Springer Publishing Company

Access to resources Recommend Favorite